ArticleHealth science reports2025
The Clinical Value of Inflammatory Indicators at the Time of Secondary Infection After Treatment With Tocilizumab: A Cross-Sectional Study.
Article in Health science reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Tocilizumab, an anti-inflammatory agent used in severe COVID-19 infection, is known to inhibit the Interleukin 6 receptor and reduce C-reactive protein (CRP) resulting in an increased risk of secondary infections. However, the trend of secondary infection and the relative inflammatory response after tocilizumab use has been reported variably. Methods: In this observational cross-sectional study, the time to normalization of CRP, rate of secondary infections, significance of infection indicators (CRP and white blood cell (WBC) count) at the time of secondary infections, length of intensive care unit (ICU) stay, and survival rate were evaluated in patients with severe COVID-19 infection after tocilizumab use. Results: A total of 216 patients (118 tocilizumab receivers vs. 98 nonreceivers) were included in this study. A higher rate of blood-stream infection ( Conclusion: Tocilizumab can increase the risk of secondary infections, while CRP levels may remain suppressed at the time. Therefore, CRP may not be suggested as a reliable marker of infection in tocilizumab users, although WBC count may remain a consistent value in confirming secondary infections in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.